Topical herpes simplex virus 2 (HSV-2) vaccination with human papillomavirus vectors expressing gB/gD ectodomains induces genital-tissue-resident memory CD8+ T cells and reduces genital disease and viral shedding after HSV-2 challenge

Journal of Virology

Volumn 89, Issue 1, 2015, Pages 83-96

  Çuburu, Nicolas ^a   Wang, Kening ^b   Goodman, Kyle N ^b   Pang, Yuk Ying ^a   Thompson, Cynthia D ^a   Lowy, Douglas R ^a   Cohen, Jeffrey I ^b   Schiller, John T ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM POTASSIUM SULFATE; GAMMA INTERFERON; GLYCOPROTEIN B; GLYCOPROTEIN D; HERPES SIMPLEX VACCINE; HERPES SIMPLEX VIRUS 2 VACCINE; NEUTRALIZING ANTIBODY; PHOSPHORYL LIPID A; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VIRUS VECTOR; GLYCOPROTEIN B, HERPES SIMPLEX VIRUS TYPE 2; GLYCOPROTEIN D-HERPES SIMPLEX VIRUS TYPE 2; HERPES VACCINE; RECOMBINANT PROTEIN; RECOMBINANT VACCINE; VIRUS ANTIBODY; VIRUS ENVELOPE PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY TITER; ARTICLE; C57BL 6 MOUSE; CD8+ T LYMPHOCYTE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; GENITAL HERPES; GENITAL SYSTEM; HERPES SIMPLEX VIRUS 2; IMMUNIZATION; IMMUNOFLUORESCENCE; IMMUNOGENICITY; MOUSE; NONHUMAN; PAPILLOMA VIRUS; PLASMID; SURVIVAL; VACCINATION; VIRUS SHEDDING; ANIMAL; BLOOD; C57BL MOUSE; DISEASE MODEL; GENE VECTOR; GENETICS; HERPES GENITALIS; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVAGINAL DRUG ADMINISTRATION; PAPILLOMAVIRIDAE; PATHOLOGY; PROCEDURES; SECRETION (PROCESS);

HUMAN HERPESVIRUS 2; HUMAN PAPILLOMAVIRUS; MUS; SIMPLEXVIRUS;

ADMINISTRATION, INTRAVAGINAL; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CD8-POSITIVE T-LYMPHOCYTES; DISEASE MODELS, ANIMAL; FEMALE; GENETIC VECTORS; HERPES GENITALIS; HERPESVIRUS 2, HUMAN; HERPESVIRUS VACCINES; IMMUNOLOGIC MEMORY; INJECTIONS, INTRAMUSCULAR; INTERFERON-GAMMA; MICE, INBRED C57BL; PAPILLOMAVIRIDAE; RECOMBINANT PROTEINS; SURVIVAL ANALYSIS; TUMOR NECROSIS FACTOR-ALPHA; VACCINATION; VACCINES, SYNTHETIC; VIRAL ENVELOPE PROTEINS; VIRUS SHEDDING;

EID: 84919429689     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.02380-14     Document Type: Article

References (66)

1. Looker KJ, Garnett GP, Schmid GP. 2008. An estimate of the global prevalence and incidence of herpes simplex virus type 2 infection. Bull World Health Organ 86:805A-812A.
2. Bradley H, Markowitz LE, Gibson T, McQuillan GM. 2014. Seroprevalence of herpes simplex virus types 1 and 2-United States, 1999-2010. J Infect Dis 209:325-333. http://dx.doi.org/10.1093/infdis/jit458.
3. Koelle DM, Corey L. 2008. Herpes simplex: insights on pathogenesis and possible vaccines. Annu Rev Med 59:381-395. http://dx.doi.org/10.1146/annurev.med.59.061606.095540.
4. Freeman EE, Weiss HA, Glynn JR, Cross PL, Whitworth JA, Hayes RJ. 2006. Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies. AIDS 20:73-83. http://dx.doi.org/10.1097/01.aids.0000198081.09337.a7.
5. Schiffer JT, Wald A, Selke S, Corey L, Magaret A. 2011. The kinetics of mucosal herpes simplex virus-2 infection in humans: evidence for rapid viral-host interactions. J Infect Dis 204:554-561. http://dx.doi.org/10.1093/infdis/jir314.
6. Koelle DM, Benedetti J, Langenberg A, Corey L. 1992. Asymptomatic reactivation of herpes simplex virus in women after the first episode of genital herpes. Ann Intern Med 116:433-437. http://dx.doi.org/10.7326/0003-4819-116-6-433.
7. Johnston C, Koelle DM, Wald A. 2011. HSV-2: in pursuit of a vaccine. J Clin Invest 121:4600-4609. http://dx.doi.org/10.1172/JCI57148.
8. + T cells and protects against herpes simplex virus type 2 challenge. Mucosal Immunol 2:129-143. http://dx.doi.org/10.1038/mi.2008.81.
9. Wizel B, Persson J, Thorn K, Nagy E, Harandi AM. 2012. Nasal and skin delivery of IC31-adjuvanted recombinant HSV-2 gD protein confers protection against genital herpes. Vaccine 30:4361-4368. http://dx.doi.org/10.1016/j.vaccine.2012.02.019.
10. Veselenak RL, Shlapobersky M, Pyles RB, Wei Q, Sullivan SM, Bourne N. 2012. A Vaxfectin-adjuvanted HSV-2 plasmid DNA vaccine is effective for prophylactic and therapeutic use in the guinea pig model of genital herpes. Vaccine 30:7046-7051. http://dx.doi.org/10.1016/j.vaccine.2012.09.057.
11. Skoberne M, Cardin R, Lee A, Kazimirova A, Zielinski V, Garvie D, Lundberg A, Larson S, Bravo FJ, Bernstein DI, Flechtner JB, Long D. 2013. An adjuvanted herpes simplex virus 2 subunit vaccine elicits a T cell response in mice and is an effective therapeutic vaccine in guinea pigs. J Virol 87:3930-3942. http://dx.doi.org/10.1128/JVI.02745-12.
12. Shlapobersky M, Marshak JO, Dong L, Huang ML, Wei Q, Chu A, Rolland A, Sullivan S, Koelle DM. 2012. Vaxfectin-adjuvanted plasmid DNA vaccine improves protection and immunogenicity in a murine model of genital herpes infection. J Gen Virol 93:1305-1315. http://dx.doi.org/10.1099/vir.0.040055-0.
13. Orr MT, Orgun NN, Wilson CB, Way SS. 2007. Recombinant Listeria monocytogenes expressing a single immune-dominant peptide confers protective immunity to herpes simplex virus-1 infection. J Immunol 178: 4731-4735. http://dx.doi.org/10.4049/jimmunol.178.8.4731.
14. Morrison LA, Da Costa XJ, Knipe DM. 1998. Influence of mucosal and parenteral immunization with a replication-defective mutant of HSV-2 on immune responses and protection from genital challenge. Virology 243:178-187. http://dx.doi.org/10.1006/viro.1998.9047.
15. Meignier B, Jourdier TM, Norrild B, Pereira L, Roizman B. 1987. Immunization of experimental animals with reconstituted glycoprotein mixtures of herpes simplex virus 1 and 2: protection against challenge with virulent virus. J Infect Dis 155:921-930. http://dx.doi.org/10.1093/infdis/155.5.921.
16. + T cells. J Virol 69:4711-4716.
17. Hoshino Y, Pesnicak L, Dowdell KC, Lacayo J, Dudek T, Knipe DM, Straus SE, Cohen JI. 2008. Comparison of immunogenicity and protective efficacy of genital herpes vaccine candidates herpes simplex virus 2 dl5-29 and dl5-29-41L in mice and guinea pigs. Vaccine 26:4034-4040. http://dx.doi.org/10.1016/j.vaccine.2008.05.022.
18. Gallichan WS, Rosenthal KL. 1995. Specific secretory immune responses in the female genital tract following intranasal immunization with a recombinant adenovirus expressing glycoprotein B of herpes simplex virus. Vaccine 13:1589-1595. http://dx.doi.org/10.1016/0264-410X(95)00100-F.
19. Dutton JL, Li B, Woo WP, Marshak JO, Xu Y, Huang ML, Dong L, Frazer IH, Koelle DM. 2013. A novel DNA vaccine technology conveying protection against a lethal herpes simplex viral challenge in mice. PLoS One 8:e76407. http://dx.doi.org/10.1371/journal.pone.0076407.
20. Da Costa X, Kramer MF, Zhu J, Brockman MA, Knipe DM. 2000. Construction, phenotypic analysis, and immunogenicity of a UL5/UL29 double deletion mutant of herpes simplex virus 2. J Virol 74:7963-7971. http://dx.doi.org/10.1128/JVI.74.17.7963-7971.2000.
21. Belshe RB, Leone PA, Bernstein DI, Wald A, Levin MJ, Stapleton JT, Gorfinkel I, Morrow RL, Ewell MG, Stokes-Riner A, Dubin G, Heineman TC, Schulte JM, Deal CD, Herpevac Trial for Women. 2012. Efficacy results of a trial of a herpes simplex vaccine. N Engl J Med 366: 34-43. http://dx.doi.org/10.1056/NEJMoa1103151.
22. Awasthi S, Belshe RB, Friedman HM. 2014. Better neutralization of herpes simplex virus type 1 (HSV-1) than HSV-2 by antibody from recipients of GlaxoSmithKline HSV-2 glycoprotein D2 subunit vaccine. J Infect Dis 210:571-575. http://dx.doi.org/10.1093/infdis/jiu177.
23. Ouwendijk WJ, Laing KJ, Verjans GM, Koelle DM. 2013. T-cell immunity to human alphaherpesviruses. Curr Opin Virol 3:452-460. http://dx.doi.org/10.1016/j.coviro.2013.04.004.
24. Simmons A, Tscharke DC. 1992. Anti-CD8 impairs clearance of herpes simplex virus from the nervous system: implications for the fate of virally infected neurons. J Exp Med 175:1337-1344. http://dx.doi.org/10.1084/jem.175.5.1337.
25. + T cells can block herpes simplex virus type 1 (HSV-1) reactivation from latency in sensory neurons. J Exp Med 191:1459-1466. http://dx.doi.org/10.1084/jem.191.9.1459.
26. Iijima N, Linehan MM, Zamora M, Butkus D, Dunn R, Kehry MR, Laufer TM, Iwasaki A. 2008. Dendritic cells and B cells maximize mucosal Th1 memory response to herpes simplex virus. J Exp Med 205:3041-3052. http://dx.doi.org/10.1084/jem.20082039.
27. Svensson A, Tunback P, Nordstrom I, Shestakov A, Padyukov L, Eriksson K. 2012. STAT4 regulates antiviral gamma interferon responses and recurrent disease during herpes simplex virus 2 infection. J Virol 86:9409-9415. http://dx.doi.org/10.1128/JVI.00947-12.
28. Milligan GN, Bernstein DI, Bourne N. 1998. T lymphocytes are required for protection of the vaginal mucosae and sensory ganglia of immune mice against reinfection with herpes simplex virus type 2. J Immunol 160:6093-6100.
29. Gebhardt T, Wakim LM, Eidsmo L, Reading PC, Heath WR, Carbone FR. 2009. Memory T cells in nonlymphoid tissue that provide enhanced local immunity during infection with herpes simplex virus. Nat Immunol 10:524-530. http://dx.doi.org/10.1038/ni.1718.
30. Mackay LK, Stock AT, Ma JZ, Jones CM, Kent SJ, Mueller SN, Heath WR, Carbone FR, Gebhardt T. 2012. Long-lived epithelial immunity by tissue-resident memory T (TRM) cells in the absence of persisting local antigen presentation. Proc Natl Acad Sci USA 109:7037-7042. http://dx.doi.org/10.1073/pnas.1202288109.
31. Shin H, Iwasaki A. 2012. A vaccine strategy that protects against genital herpes by establishing local memory T cells. Nature 491:463-467. http://dx.doi.org/10.1038/nature11522.
32. + skin-resident T cells in human herpes virus infection. Nature 497:494-497. http://dx.doi.org/10.1038/nature12110.
33. + T cells accumulate near sensory nerve endings in genital skin during subclinical HSV-2 reactivation. J Exp Med 204:595-603. http://dx.doi.org/10.1084/jem.20061792.
34. Schiffer JT, Swan D, Al Sallaq R, Magaret A, Johnston C, Mark KE, Selke S, Ocbamichael N, Kuntz S, Zhu J, Robinson B, Huang ML, Jerome KR, Wald A, Corey L. 2013. Rapid localized spread and immunologic containment define herpes simplex virus-2 reactivation in the human genital tract. eLife 2:e00288. http://dx.doi.org/10.7554/eLife.00288.
35. Gillgrass AE, Tang VA, Towarnicki KM, Rosenthal KL, Kaushic C. 2005. Protection against genital herpes infection in mice immunized under different hormonal conditions correlates with induction of vaginaassociated lymphoid tissue. J Virol 79:3117-3126. http://dx.doi.org/10.1128/JVI.79.5.3117-3126.2005.
36. McDermott MR, Smiley JR, Leslie P, Brais J, Rudzroga HE, Bienenstock J. 1984. Immunity in the female genital tract after intravaginal vaccination of mice with an attenuated strain of herpes simplex virus type 2. J Virol 51:747-753.
37. Roberts JN, Buck CB, Thompson CD, Kines R, Bernardo M, Choyke PL, Lowy DR, Schiller JT. 2007. Genital transmission of HPV in a mouse model is potentiated by nonoxynol-9 and inhibited by carrageenan. Nat Med 13:857-861. http://dx.doi.org/10.1038/nm1598.
38. + T cell responses. J Clin Invest 122:4606-4620. http://dx.doi.org/10.1172/JCI63287.
39. Gordon SN, Kines RC, Kutsyna G, Ma ZM, Hryniewicz A, Roberts JN, Fenizia C, Hidajat R, Brocca-Cofano E, Çuburu N, Buck CB, Bernardo ML, Robert-Guroff M, Miller CJ, Graham BS, Lowy DR, Schiller JT, Franchini G. 2012. Targeting the vaginal mucosa with human papillomavirus pseudovirion vaccines delivering simian immunodeficiency virus DNA. J Immunol 188:714-723. http://dx.doi.org/10.4049/jimmunol.1101404.
40. Graham BS, Kines RC, Corbett KS, Nicewonger J, Johnson TR, Chen M, LaVigne D, Roberts JN, Çuburu N, Schiller JT, Buck CB. 2010. Mucosal delivery of human papillomavirus pseudovirus-encapsidated plasmids improves the potency of DNA vaccination. Mucosal Immunol 3:475-486. http://dx.doi.org/10.1038/mi.2010.31.
41. Bender FC, Whitbeck JC, Lou H, Cohen GH, Eisenberg RJ. 2005. Herpes simplex virus glycoprotein B binds to cell surfaces independently of heparan sulfate and blocks virus entry. J Virol 79:11588-11597. http://dx.doi.org/10.1128/JVI.79.18.11588-11597.2005.
42. Buck CB, Pastrana DV, Lowy DR, Schiller JT. 2004. Efficient intracellular assembly of papillomaviral vectors. J Virol 78:751-757. http://dx.doi.org/10.1128/JVI.78.2.751-757.2004.
43. Wang K, Kappel JD, Canders C, Davila WF, Sayre D, Chavez M, Pesnicak L, Cohen JI. 2012. A herpes simplex virus 2 glycoprotein D mutant generated by bacterial artificial chromosome mutagenesis is severely impaired for infecting neuronal cells and infects only Vero cells expressing exogenous HVEM. J Virol 86:12891-12902. http://dx.doi.org/10.1128/JVI.01055-12.
44. Pastrana DV, Buck CB, Pang YY, Thompson CD, Castle PE, FitzGerald PC, Kruger Kjaer S, Lowy DR, Schiller JT. 2004. Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18. Virology 321:205-216. http://dx.doi.org/10.1016/j.virol.2003.12.027.
45. Trus BL, Roden RB, Greenstone HL, Vrhel M, Schiller JT, Booy FP. 1997. Novel structural features of bovine papillomavirus capsid revealed by a three-dimensional reconstruction to 9 Å resolution. Nat Struct Biol 4:413-420. http://dx.doi.org/10.1038/nsb0597-413.
46. Murata T, Goshima F, Takakuwa H, Nishiyama Y. 2002. Excretion of herpes simplex virus type 2 glycoproteinDinto the culture medium. J Gen Virol 83:2791-2795.
47. Hanke T, Graham FL, Rosenthal KL, Johnson DC. 1991. Identification of an immunodominant cytotoxic T-lymphocyte recognition site in glycoprotein B of herpes simplex virus by using recombinant adenovirus vectors and synthetic peptides. J Virol 65:1177-1186.
48. Wallace ME, Keating R, Heath WR, Carbone FR. 1999. The cytotoxic T-cell response to herpes simplex virus type 1 infection of C57BL/6 mice is almost entirely directed against a single immunodominant determinant. J Virol 73:7619-7626.
49. Porgador A, Staats HF, Faiola B, Gilboa E, Palker TJ. 1997. Intranasal immunization with CTL epitope peptides from HIV-1 or ovalbumin and the mucosal adjuvant cholera toxin induces peptide-specific CTLs and protection against tumor development in vivo. J Immunol 158:834-841.
50. Carbone FR, Mackay LK, Heath WR, Gebhardt T. 2013. Distinct resident and recirculating memory T cell subsets in non-lymphoid tissues. Curr Opin Immunol 25:329-333. http://dx.doi.org/10.1016/j.coi.2013.05.007.
51. + tissue-resident memory T cells of skin. Nat Immunol 14:1294-1301. http://dx.doi.org/10.1038/ni.2744.
52. Seder RA, Darrah PA, Roederer M. 2008. T-cell quality in memory and protection: implications for vaccine design. Nat Rev Immunol 8:247-258. http://dx.doi.org/10.1038/nri2274.
53. Hoshino Y, Pesnicak L, Dowdell KC, Burbelo PD, Knipe DM, Straus SE, Cohen JI. 2009. Protection from herpes simplex virus (HSV)-2 infection with replication-defective HSV-2 or glycoprotein D2 vaccines in HSV-1-seropositive and HSV-1-seronegative guinea pigs. J Infect Dis 200: 1088-1095. http://dx.doi.org/10.1086/605645.
54. Henning P, Gustafsson T, Flach CF, Hua YJ, Strombeck A, Holmgren J, Lindholm L, Yrlid U. 2011. The subcellular location of antigen expressed by adenoviral vectors modifies adaptive immunity but not dependency on cross-presenting dendritic cells. Eur J Immunol 41:2185-2196. http://dx.doi.org/10.1002/eji.201041009.
55. Higgins TJ, Herold KM, Arnold RL, McElhiney SP, Shroff KE, Pachuk CJ. 2000. Plasmid DNA-expressed secreted and nonsecreted forms of herpes simplex virus glycoprotein D2 induce different types of immune responses. J Infect Dis 182:1311-1320. http://dx.doi.org/10.1086/315879.
56. Hu H, Eller MA, Zafar S, Zhou Y, Gu M, Wei Z, Currier JR, Marovich MA, Kibuuka HN, Bailer RT, Koup RA, Robb ML, Michael NL, Kim JH, Ratto-Kim S. 2014. Preferential infection of human Ad5-specific CD4 T cells by HIV in Ad5 naturally exposed and recombinant Ad5-HIV vaccinated individuals. Proc Natl Acad Sci USA 111:13439-13444. http://dx.doi.org/10.1073/pnas.1400446111.
57. + T cell subset coexpressing multiple markers of HIV susceptibility. J Immunol 187:6032-6042. http://dx.doi.org/10.4049/jimmunol.1101836.
58. 7 forms a complex with cell-surface CD4 and defines a T-cell subset that is highly susceptible to infection by HIV-1. Proc Natl Acad Sci USA 106:20877-20882. http://dx.doi.org/10.1073/pnas.0911796106.
59. Marshak JO, Dong L, Koelle DM. 2014. The murine intravaginal HSV-2 challenge model for investigation of DNA vaccines. Methods Mol Biol 1144:305-327. http://dx.doi.org/10.1007/978-1-4939-0428-0_21.
60. Dudley KL, Bourne N, Milligan GN. 2000. Immune protection against HSV-2 in B-cell-deficient mice. Virology 270:454-463. http://dx.doi.org/10.1006/viro.2000.0298.
61. Openshaw H, Asher LV, Wohlenberg C, Sekizawa T, Notkins AL. 1979. Acute and latent infection of sensory ganglia with herpes simplex virus: immune control and virus reactivation. J Gen Virol 44:205-215. http://dx.doi.org/10.1099/0022-1317-44-1-205.
62. + T cells continuously patrol skin epithelia to quickly recognize local antigen. Proc Natl Acad Sci USA 109:19739-19744. http://dx.doi.org/10.1073/pnas.1208927109.
63. Bright H, Perez DL, Christy C, Cockle P, Eyles JE, Hammond D, Khodai T, Lang S, West K, Loudon PT. 2012. The efficacy of HSV-2 vaccines based on gD and gB is enhanced by the addition of ICP27. Vaccine 30:7529-7535. http://dx.doi.org/10.1016/j.vaccine.2012.10.046.
64. Haynes JR, Arrington J, Dong L, Braun RP, Payne LG. 2006. Potent protective cellular immune responses generated by a DNA vaccine encoding HSV-2 ICP27 and the E. coli heat labile enterotoxin. Vaccine 24:5016-5026. http://dx.doi.org/10.1016/j.vaccine.2006.03.046.
65. Milligan GN, Bernstein DI. 1997. Interferon-gamma enhances resolution of herpes simplex virus type 2 infection of the murine genital tract. Virology 229:259-268. http://dx.doi.org/10.1006/viro.1997.8441.
66. Coen DM, Kosz-Vnenchak M, Jacobson JG, Leib DA, Bogard CL, Schaffer PA, Tyler KL, Knipe DM. 1989. Thymidine kinase-negative herpes simplex virus mutants establish latency in mouse trigeminal ganglia but do not reactivate. Proc Natl Acad Sci USA 86:4736-4740. http://dx.doi.org/10.1073/pnas.86.12.4736.